Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Incorporated (INSM) has announced the granting of inducement awards to 19 new employees. The awards, approved by Insmed's Compensation Committee under NASDAQ Listing Rule 5635(c)(4), were made as material inducement for employment.
The employees received options on January 2, 2025, to purchase a total of 65,930 shares of Insmed common stock at an exercise price of $69.95 per share, matching the closing price on the Nasdaq Global Select Market on the grant date.
The options come with a 10-year term and a four-year vesting schedule, with 25% vesting after the first year and 12.5% vesting every six months thereafter until the fourth anniversary, contingent on continued employment.
Insmed Incorporated (INSM) ha annunciato il conferimento di premi incentivanti a 19 nuovi dipendenti. I premi, approvati dal Comitato per la Compensazione di Insmed sotto la Regola di Quotazione NASDAQ 5635(c)(4), sono stati concessi come incentivazione materiale per l'assunzione.
I dipendenti hanno ricevuto opzioni il 2 gennaio 2025, per acquistare un totale di 65.930 azioni di azioni ordinarie Insmed a un prezzo di esercizio di 69,95 dollari per azione, corrispondente al prezzo di chiusura sul Nasdaq Global Select Market nella data di assegnazione.
Le opzioni hanno un termine di 10 anni e un programma di maturazione di quattro anni, con il 25% che matura dopo il primo anno e il 12,5% che matura ogni sei mesi successivamente fino al quarto anniversario, subordinato alla continuazione dell'impiego.
Insmed Incorporated (INSM) ha anunciado la concesión de premios de incentivo a 19 nuevos empleados. Los premios, aprobados por el Comité de Compensación de Insmed bajo la Regla de Cotización NASDAQ 5635(c)(4), se entregaron como un incentivo material para el empleo.
Los empleados recibieron opciones el 2 de enero de 2025 para comprar un total de 65,930 acciones de acciones ordinarias de Insmed a un precio de ejercicio de $69.95 por acción, coincidiendo con el precio de cierre en el Nasdaq Global Select Market en la fecha de concesión.
Las opciones tienen un plazo de 10 años y un cronograma de consolidación de cuatro años, con un 25% que se consolida después del primer año y un 12.5% que se consolida cada seis meses hasta el cuarto aniversario, sujeto a la continuación del empleo.
인스메드 주식회사 (INSM)는 19명의 새로운 직원에게 유인 인센티브를 제공했다고 발표했습니다. 이 인센티브는 NASDAQ 상장 규정 5635(c)(4)에 따라 인스메드 보상 위원회에서 승인되었습니다.
직원들은 2025년 1월 2일에 인스메드 보통주 65,930주를 주당 $69.95의 행사가로 구매할 수 있는 옵션을 받았으며, 이는 부여일의 Nasdaq Global Select Market에서의 종가와 일치합니다.
옵션은 10년의 유효 기간과 4년의 탄력적 일정을 가지고 있으며, 첫 해에 25%가 성립되고 이후 6개월마다 12.5%가 탄력적으로 성립됩니다. 이는 계속 고용되는 조건 하에 이루어집니다.
Insmed Incorporated (INSM) a annoncé l'octroi de primes d'incitation à 19 nouveaux employés. Les primes, approuvées par le Comité de Rémunération d'Insmed sous la règle de cotation NASDAQ 5635(c)(4), ont été accordées comme une incitation matérielle à l'emploi.
Les employés ont reçu des options le 2 janvier 2025 pour acheter un total de 65,930 actions ordinaires d'Insmed à un prix d'exercice de 69,95 $ par action, correspondant au prix de clôture sur le Nasdaq Global Select Market à la date de l'octroi.
Les options ont une durée de 10 ans et un calendrier d'acquisition de quatre ans, avec 25 % d'acquisition après la première année et 12,5 % d'acquisition tous les six mois jusqu'au quatrième anniversaire, sous réserve de la continuité de l'emploi.
Die Insmed Incorporated (INSM) hat die Vergabe von Anreizprämien an 19 neue Mitarbeiter angekündigt. Die Prämien, die vom Vergütungsausschuss von Insmed gemäß der NASDAQ-Notierungsregel 5635(c)(4) genehmigt wurden, wurden als wesentlicher Anreiz für die Beschäftigung gewährt.
Die Mitarbeiter erhielten am 2. Januar 2025 Optionen zum Kauf von insgesamt 65.930 Aktien der Stammaktien von Insmed zu einem Ausübungspreis von 69,95 $ pro Aktie, was dem Schlusskurs am Nasdaq Global Select Market am Tag der Vergabe entspricht.
Die Optionen haben eine Laufzeit von 10 Jahren und einen Vesting-Zeitplan von vier Jahren, wobei 25 % nach dem ersten Jahr und 12,5 % alle sechs Monate bis zum vierten Jahrestag anfallen, vorausgesetzt, die Beschäftigung wird fortgesetzt.
- Stock options granted at market price ($69.95) align employee and shareholder interests
- Four-year vesting schedule promotes employee retention
- Expanded workforce with 19 new hires indicates company growth
- Potential future dilution from 65,930 new stock options
In connection with the commencement of their employment, the employees received options on January 2, 2025, to purchase an aggregate 65,930 shares of Insmed common stock at an exercise price of
The options have a 10-year term and a four-year vesting schedule, with
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in Bridgewater,
Contact:
Investors:
Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
bryan.dunn@insmed.com
Michael V. Morabito, Ph.D.
Director, Investor Relations
(917) 936-8430
michael.morabito@insmed.com
Gianna De Palma
Manager, Investor Relations
(973) 886-2236
gianna.depalma@insmed.com
Media:
Mandy Fahey
Vice President, Corporate Communications
(732) 718-3621
amanda.fahey@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302341905.html
SOURCE Insmed Incorporated
FAQ
How many shares of INSM stock options were granted to new employees on January 2, 2025?
What is the exercise price for INSM's January 2025 inducement stock options?
What is the vesting schedule for INSM's January 2025 inducement stock options?
How long is the term of INSM's January 2025 inducement stock options?
How many new employees received INSM stock options in January 2025?
